Pfizer is also studying the treatment's impact on people at low risk of Covid illness and on those who have already been exposed to the virus by someone in their household.
An experimental pill to treat Covid developed by the US company Pfizer cuts the risk of hospitalisation or death by 89% in vulnerable adults, clinical trial results suggest.
The drug - Paxlovid - is intended for use soon after symptoms develop in people at high risk of severe disease.
It comes
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
